Teva- Pharmaceutical Industries Goodwill

Teva- Pharmaceutical Industries's goodwill stands at $16B as of June 2026. That compares with $16B in the prior-year period — down 0.7% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Teva- Pharmaceutical Industries reported $16B in goodwill versus $16B a year earlier — a 0.7% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $16B in the prior-year period — down 0.7% year over year. Sustained growth in goodwill can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Teva- Pharmaceutical Industries's goodwill evolved across reporting periods, while the comparison chart places TEVA next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, goodwill is commonly used to spot outliers. Teva- Pharmaceutical Industries's reading of $16B is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.